Drug Profile
Betrixaban - Alexion AstraZeneca Rare Disease
Alternative Names: Bevyxxa; Dexxience; MK-4448; MLN-1021; PRT 021; PRT 054021Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Millennium Pharmaceuticals
- Developer Alexion AstraZeneca Rare Disease; Portola Pharmaceuticals
- Class Anticoagulants; Antithrombotics; Benzamides; Chlorinated hydrocarbons; Imines; Pyridines; Small molecules; Vascular disorder therapies
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Venous thromboembolism
- Discontinued Stroke
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Venous thromboembolism(In adolescents, In children, In infants, In neonates, Prevention) in Russia (PO, Capsule)
- 16 Apr 2021 Discontinued - Preregistration for Venous thromboembolism (Prevention) in European Union (PO)
- 10 Nov 2018 Interim sub-group analysis efficacy data from a phase III APEX trial in venous thromboembolism presented at the 91st Annual Scientific Sessions of the American Heart Association (AHA-2018)